MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

IBN Announces Latest Episode of The TechMediaWire Podcast featuring Justin Hanka, CEO of MindBio Therapeutics Corp.

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Leveraging AI, Voice Analysis to Develop Intoxication Detection

MindBio Announces Closing of Private Placement

MindBio Announces Upsize to Private Placement up to $1.5 Million

Critical Contrast: Mustang Bio (NASDAQ:MBIO) & AstraZeneca (NASDAQ:AZN)

MindBio Announces Private Placement to Raise up to $650,000

MindBio Advances Large-Scale Deployment of Voice Intoxication Detection Through Integrated Edge AI Hardware-Software Platform

CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)

Talisker Receives Assay Results from 1105 Level Lateral Development at the Mustang Mine

MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy

Dow Dips 1%; Mustang Bio Shares Spike Higher

This BlackRock stock just spiked over 300%

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Reverse Stock Split

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

Why are Mustang Bio shares (MBIO) up almost 500%?

Crude Oil Rises 1%; Mustang Bio Shares Spike Higher

Why Is Mustang Bio (MBIO) Stock Up 347% Today?

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Why Is Mustang Bio (MBIO) Stock Up 58% Today?

HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)

Mustang Bio Announces Closing of $4 Million Public Offering

Mustang Bio Announces Pricing of $4 Million Public Offering

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Mustang Bio to Participate in Two August 2023 Investor Conferences